Serious systemic adverse effects (beyond package side effects) from #fluoroquinolone (#Cipro/#ciprofloxacin, Levaquin (off market)/#levofloxacin, Avelox/#moxifloxacin etc) antibiotics may persist for extended periods, potentially lasting for years or indefinitely for some. In 2016 and 2018, the FDA advised that fluoroquinolones should only be used in cases where no other options are available for sinusitis, bronchitis, or uncomplicated UTIs. They contain multiple Black Box warnings,* the most serious warnings a medication can have. If you are experiencing any or all of these symptoms below and are stunned by the ongoing emergence of new and troublesome issues following the antibiotic treatment you underwent, you have been what is deemed 'floxed': ✅ Extreme weakness, inability to stand or walk as before prescription ✅ Nerve problems — weakness, numbness, pain, muscle jerking and twitching, crawling bug feeling ✅ Tendon tears and muscle weakness ✅ Collagen destruction, hanging skin, wounds slow to heal ✅ Acute sensitivity to sunlight, sudden hormone & thyroid issues ✅ Ringing in the ears, vision disturbances ✅ Anxiety, panic attacks, disorientation, impaired concentration or memory, confusion, depersonalization, hallucinations, psychoses Due to the potential of mitochondria** dysfunction, the actual list of adverse effects can be quite lengthy. Every prescription drug has side effects, some worse than others. Please do your research before you take that next pill, ear drop or eye drop, ask for a substitute if needed - don't let yourself become a statistic. 🟠 🟡 🟢 🔵 🟣 ⚫ 🟤 *Black Box warnings: fq100.org/fda-warnings **Mitochondria are the powerhouse of your cells ➥Listen to our 3 part series with Dr. Stefan Pieper: YouTube channel: youtube.com/@FqAntibioticDam… 💊Medications in the fluoroquinolone class (incl: Cipro/ciprofloxacin, Levaquin (off market)/levofloxacin, Avelox/moxifloxacin etc) in all forms for humans and pets: fq100.org/drug-list Find support and resources on our sites: 🌐 Medical resources: fq100.org/find-medical 🧭 Help & Misc resources: fq100.org/find-help ▶️ YouTube: youtube.com/@FqAntibioticDam… 🐦 X/Twitter: twitter.com/FQ_100 #FQAwareness #Fluoroquinolones #MitochondrialHealth #AntibioticSideEffects #Floxed #Cipro #Levaquin #FQAD ⚠️Disclaimer: Fluoroquinolone Toxicity Study does not provide medical advice, and all articles and written content are intended for informational purposes only. We do our best to provide accurate information. Such information is not a substitute for professional medical advice, diagnosis or treatment. For multiple reasons, supplements, treatments, and pharmaceutical effects and outcomes can possibly vary significantly among those affected by fluoroquinolone drugs.

We have some resources for you ✏️ Dealing with fluoroquinolone antibiotic adverse effects and an upcoming doctor appointment? Feeling isolated and lost? We want you to feel a little more prepared and a little less alone. Last year when the code came out, we put some supportive tools in one place on our website so you do not have to reinvent the wheel on a day when your body and brain may already be doing a lot. 🟣A printable ICD-10 code sheet you can bring with you ICD-10 simply means the standardized diagnosis and billing codes used in medical records and by insurance. As of October 1, 2025, fluoroquinolone adverse effects/toxicity have their own ICD-10 code category. That can make it easier for a clinician to document your reaction accurately and consistently. ➦Check out the code list, included FDA warnings and Black Box timeline to print and take with you in the downloads section. 🟣Asking for the Code Some possible helpful guidance on how to ask your doctor to enter the code into your medical record ➦Check out this document in the downloads section. 🟣The Adverse Effects Evaluation Form Many people tell us the hardest part of an appointment is remembering everything their body is experiencing, especially adverse effects that are ever-changing and piling up. This downloadable form helps you check-off what you have experienced, when it started, and what changed over time, so you can walk in with a clear snapshot of top complaints. ➦Check out this form in the downloads section. 🟣Medical care If you are looking for a clinician who may be more open to documenting complex reactions, our Find Medical page gives some options. ➦Check out our Dear Doctor letters in the downloads section on the Find Help page in addition; another document that may help support your visit 🟣Support in the community Seek comfort in a like-minded community via our Find Support page reflecting groups in multiple countries. Even one kind conversation with someone who gets it can make a tough day feel a bit lighter, despite the huge challenges we are all facing. ➦See the support group page link below ➤ ➤ ➤ ➤ ➤ ➤ Start here❗ (best first step & for downloads): fq100.org/find-help 🌈🌈🌈If you already took the code information to an appointment, please share how it went in the comment section below. Feedback can help others, determine if we need to add more to references, and get an idea of what hurdles floxies are still facing at appointments. 🟣🟣🟣🟣🟣🟣🟣🟣🟣🟣🟣🟣🟣 Find Medical: fq100.org/find-medical Find Support: fq100.org/find-support 💊Medications in the fluoroquinolone class (incl: Cipro/ciprofloxacin, Levaquin (off market)/levofloxacin, Avelox/moxifloxacin etc) in all forms for humans and pets: fq100.org/drug-list Looking for more info? Check out our past Facebook posts and our YouTube channel: ▶️: youtube.com/@FqAntibioticDam… #Fluoroquinolones #FQAD #FQToxicity #Mitochondria #Neuropathy #AntibioticSideEffects #Cipro #Levofloxacin

Mitochondria 101 for Fluoroquinolone Associated Disability ✏️Fluoroquinolone Associated Disability (FQAD) This is an FDA term whose definition is: A constellation of disabling symptoms in two or more body systems lasting 30 days or longer after the prescription* is finished. To see the complete definition and indicated body systems, please visit: fq100.org/fda-warnings Watch this video here: youtube.com/watch?v=v7mYIiPH… *💊Medications in the fluoroquinolone class (incl: Cipro/ciprofloxacin, Levaquin (off market)/levofloxacin, Avelox/moxifloxacin etc) in all forms for humans and pets: fq100.org/drug-list Find support and resources on our sites: 🌐 Website & Resources: fq100.org/ ▶️ YouTube: youtube.com/@FqAntibioticDam… 🔵 Facebook: facebook.com/fqtoxicitystudy… 🐦 X/Twitter: twitter.com/FQ_100 #Fluoroquinolones #FQAD #FQToxicity #Mitochondria #Neuropathy #AntibioticSideEffects #Cipro #Levofloxacin

Have you ever felt like your body’s thermostat stopped working after fluoroquinolone antibiotics? After fluoroquinolone injury, temperature regulation can feel unstable. Heat, cold, sun, saunas, air conditioning, or cold water can affect the body much more intensely than they used to. Instead of adjusting normally, the body may struggle to find its way back to a comfortable baseline after becoming too hot or too cold. Fluoroquinolone* antibiotics have been linked in scientific literature to mitochondrial stress, oxidative stress, and nervous system adverse effects. These effects may help explain why temperature regulation can feel so disrupted for some people. Hot weather, direct sun, saunas, strong air conditioning, cold weather, cold water, or being chilled for too long can trigger or worsen symptoms in different ways. So why might this happen – some plausible thoughts….. The body regulates temperature through a complex network involving mitochondria, metabolism, the autonomic nervous system, blood sugar, hormones, inflammation, circulation, and the brain’s temperature-control centers. 🌀 Mitochondria play an important role because they help produce cellular energy. When mitochondria are under stress, cells may not produce energy as efficiently. That matters because energy production is closely tied to heat production, metabolism, and the body’s ability to keep temperature stable. Brown fat, which helps the body generate heat, is especially dependent on healthy mitochondrial function. Research shows that brown adipose tissue contains mitochondria that are highly involved in heat production and thermogenesis. The autonomic nervous system is another piece of the puzzle. This is the part of the nervous system that helps control sweating, blood vessel constriction and dilation, heart rate, and other automatic functions. When it is not regulating well, temperature changes can bring on chills, flushing, overheating, shakiness, weakness, or trouble adjusting normally. 🔥 Heat exposure can place extra demand on this system. Hot weather, direct sun, exercise in heat, saunas, or hot tubs make the body work harder to cool itself and maintain circulation. That may help explain why people with fluoroquinolone-associated injury can experience poor heat tolerance, worsening symptoms after sun or sauna exposure, trouble cooling down once overheated, or an increased heart rate in heat or direct sun. The heart rate piece can be especially unsettling. In heat, the heart may beat faster as the body tries to move blood toward the skin to release heat. For people with autonomic instability, this normal cooling response can become exaggerated, uncomfortable, or difficult to calm down. ❄️Cold can be difficult too. When the body gets too cold, it has to work harder to maintain core temperature through shivering, blood vessel tightening, stress-hormone signaling, and increased metabolic demand. For someone already dealing with mitochondrial stress, nervous system sensitivity, circulation issues, or dysautonomia**-like symptoms, cold weather, strong air conditioning, cold water, or being chilled too long can feel especially draining and may worsen fatigue, muscle tightness, tremors, weakness, pain, or temperature instability. Inflammation and oxidative stress may add another layer. Mitochondrial dysfunction can increase reactive oxygen species, which may further disrupt cellular signaling and nervous system stability. Several studies and reviews discuss fluoroquinolone-related mitochondrial dysfunction, oxidative stress, and possible vulnerability in people with reduced antioxidant defenses or mitochondrial susceptibility. ✅ For those living with fluoroquinolone-associated injury, the focus is often on reducing extra stress on the body rather than pushing through symptoms. This can include pacing activity, resting after exertion, staying hydrated, considering electrolytes when appropriate, and being cautious with temperature extremes such as direct sun, saunas, hot tubs, strong air conditioning, cold water, or prolonged cold exposure. It may also be helpful to speak with a doctor in functional medicine about thyroid function, anemia, blood sugar regulation, dehydration, electrolyte imbalance, blood pressure changes, heart rhythm concerns, symptoms related to dysautonomia, and other issues that can affect temperature control, heart rate, weakness, and fatigue. *Medications in the fluoroquinolone class (incl: Cipro/ciprofloxacin, Levaquin (off market)/levofloxacin, Avelox/moxifloxacin etc) in all forms for humans and pets: fq100.org/drug-list **Dysautonomia: is a dysfunction of the autonomic nervous system, which controls automatic body functions such as heart rate, blood pressure, temperature regulation, digestion, and sweating. Find support and resources on our sites: 🌐 Website & Resources: fq100.org/ ▶️ YouTube: youtube.com/@FqAntibioticDam… 🔵 Facebook: facebook.com/fqtoxicitystudy… 🐦 X/Twitter: twitter.com/FQ_100 References: 1. U.S. Food and Drug Administration. Ciprofloxacin Prescribing Information. Revised September 2024. accessdata.fda.gov/drugsatfd… 2. Michalak K, Sobolewska-Włodarczyk A, Włodarczyk M, Sobolewska J, Woźniak P, Sobolewski B. Treatment of the Fluoroquinolone-Associated Disability: The Pathobiochemical Implications. Oxidative Medicine and Cellular Longevity. 2017. pmc.ncbi.nlm.nih.gov/article… 3. Kalghatgi S, Spina CS, Costello JC, Liesa M, Morones-Ramirez JR, Slomovic S, Molina A, Shirihai OS, Collins JJ. Bactericidal Antibiotics Induce Mitochondrial Dysfunction and Oxidative Damage in Mammalian Cells. Science Translational Medicine. 2013;5(192):192ra85. pmc.ncbi.nlm.nih.gov/article… 4. Bertholet AM, Kirichok Y. Mitochondrial H Leak and Thermogenesis. Annual Review of Physiology. 2022;84:381-407. pmc.ncbi.nlm.nih.gov/article… 5. Crandall CG, González-Alonso J. Cardiovascular Function in the Heat-Stressed Human. Acta Physiologica. 2010;199(4):407-423. pmc.ncbi.nlm.nih.gov/article… 6. Low DA, Keller DM, Wingo JE, Brothers RM, Crandall CG. Sympathetic Nerve Activity and Whole Body Heat Stress in Humans. Journal of Applied Physiology. 2011;111(5):1329-1334. pmc.ncbi.nlm.nih.gov/article… 7. Ouzzahra Y, et al. Effect of Acute Cold Exposure on Energy Metabolism and Activity of Brown Adipose Tissue in Humans: A Systematic Review and Meta-Analysis. Frontiers in Physiology. 2022;13:917084. frontiersin.org/journals/phy… 8. Cleveland Clinic. Dysautonomia. Last reviewed September 11, 2023. my.clevelandclinic.org/healt… #Fluoroquinolones #FQAD #FQToxicity #FluoroquinoloneToxicity #Mitochondria #MitochondrialDysfunction #OxidativeStress #Dysautonomia #AutonomicNervousSystem #TemperatureRegulation #HeatIntolerance #ColdIntolerance #Neuropathy #AntibioticSideEffects #AdverseDrugReaction #DrugSafety #Cipro #Ciprofloxacin #Levofloxacin #Moxifloxacin

Research every medication, always.

We have some resources for you ✏️ Dealing with fluoroquinolone antibiotic adverse effects and an upcoming doctor appointment? Feeling isolated and lost? We want you to feel a little more prepared and a little less alone. We put some supportive tools in one place so you do not have to reinvent the wheel on a day when your body and brain may already be doing a lot. 🟣A printable ICD-10 code sheet you can bring with you ICD-10 simply means the standardized diagnosis and billing codes used in medical records and by insurance. As of October 1, 2025, fluoroquinolone adverse effects have their own ICD-10 code category. That can make it easier for a clinician to document your reaction accurately and consistently. ➦Check out the code list, included FDA warnings and Black Box timeline to print and take with you in the downloads section. 🟣The Adverse Effects Evaluation Form Many people tell us the hardest part of an appointment is remembering everything their body is experiencing, especially adverse effects that are ever-changing and piling up. This downloadable form helps you check-off what you have experienced, when it started, and what changed over time, so you can walk in with a clear snapshot. ➦Check out this form in the downloads section. 🟣Medical care If you are looking for a clinician who may be more open to documenting complex reactions, our Find Medical page shares starting points and resources to help with your search. ➦Check out our Dear Doctor letters in the downloads section 🟣Support in the community Seek comfort in a like-minded community via our Find Support page reflecting groups in multiple countries. Even one kind conversation with someone who gets it can make a tough day feel a bit lighter. ➨➨➨➨❗Start here (best first step & for downloads): fq100.org/find-help Find Medical: fq100.org/find-medical Find Support: fq100.org/find-support 💊Medications in the fluoroquinolone class (incl: Cipro/ciprofloxacin, Levaquin (off market)/levofloxacin, Avelox/moxifloxacin etc) in all forms for humans and pets: fq100.org/drug-list Looking for more info? Check out our past Facebook posts and our YouTube channel: ▶️: youtube.com/@FqAntibioticDam…

A Letter Every Doctor Should Read – From a Physician Who Was "Floxed" by a Fluoroquinolone Antibiotic: Over 10 years ago, anesthesiologist Dr. Todd R. Plumb, wrote a pertinent letter to colleagues after experiencing severe adverse effects from a common medication in the fluoroquinolone* family of antibiotics. His perspective as both doctor and patient, and his call for better awareness and more careful, compassionate care is sadly still very relevant today as we continue to fight and research for answers, awareness and treatments. The new ICD10 medical diagnosis code** was a start, but we still have much work to do. 🌀You can download this below letter, along with the publication references, from our Help page under “Downloadable Materials”, where you will also find multiple resources that may help an upcoming doctor visit go more smoothly, especially if you are seeking the medical diagnosis code for fluoroquinolones: fq100.org/find-help ➥ We also want to say this: if you are a healthcare professional who has been affected and feel hesitant to speak out, you are not alone. We welcome you to reach out to the Foundation through the Contact Us page on our website below. Dr. Plumb’s letter✏️ Dear Doctor, As you are probably aware, the fluoroquinolone class of antibiotics is useful for certain serious infections. Unfortunately, fluoroquinolones also have a long history of serious adverse drug reactions, many of them long term. [1] As a consequence of these reactions, several of these drugs have been removed from clinical practice or their use severely restricted. Besides the severe life-threatening immediate reactions, those of a more chronic nature may occur. The spectrum of these adverse reactions is extremely broad. Patients suffering from these reactions are often misdiagnosed, referred for a psychiatric consult or even unfairly labeled as "difficult patients." Many physicians have not been properly educated about the severe nature of these chronic adverse reactions, some of which result in life-long disabilities. Post-marketing studies of several flouroquinolones have shown an incidence of adverse reactions much higher than were originally reported in pre-clinical studies. [1,2,3] You are probably aware that the fluoroquinolones are eukaryotic DNA gyrase and topoisomerase inhibitors very similar to many antineoplastic agents. Because of their similar mechanisms of action, it's no surprise that fluoroquinolones and many antineoplastic agents share similar toxicity profiles. Studies have even been conducted using fluoroquinolones to inhibit neoplastic chondrocyte growth in chondrosarcoma. [4] There are many patients who have a syndrome of associated symptoms that include, but are not limited to: CNS agitation, depression, insomnia, new-onset anxiety and panic attacks, and even elevated intracranial pressure and visual abnormalities. They may also present with peripheral neuropathy usually of the small fiber type with temperature and pain sensory aberrations, but also often involving larger sensory and motor nerves. Spontaneous muscle activity with fasciculations, myokymia and myoclonic jerks may also occur. Many have musculoskeletal damage with degeneration of cartilage and tendons often leading to tendon rupture and severe ongoing musculoskeletal pain long after therapy has been discontinued. [1,2,3,4,5,6,7,8] This complex symptomatology does not usually resolve after discontinuation of the inducing fluoroquinolone and may in fact worsen. Many patients go on to have disability that may persist for years. [1] Unfortunately, such patients are often seen by many physicians from multiple specialties who, given the complex symptomatology, fail to recognize a unifying diagnosis. The mechanism of injury is not fully apparent, but several studies have been conducted and researchers have implicated the following possible mechanisms: 1. Inhibition or disruption of the CNS GABA receptor. [9] 2. Depletion of magnesium and disruption of cellular enzymatic function. [10] 3. Disruption of mitochondrial function and energy production. [11,12] 4. Oxidative injury and cellular death. [14] This seems to be a functional disorder and structural abnormalities are not usually seen on radiological studies. [13] Patients may have abnormal EMG/NCV studies, abnormal skin punch neurologic density and morphology, abnormal vasomotor and sudomotor function on autonomic testing, and abnormal degeneration of tendons and cartilage on MRI. [13] There may be a large number of these patients with coexisting endocrine abnormalities including: antithyroid antibodies and abnormal thyroid function, abnormal adrenal function with either hyper or hypocortisolism, hypogonadism, hypo or hyperglycemia and possibly impaired pituitary function. [13] Most patients suffering from these side effects have a very clear onset of symptoms temporally related to a course of fluoroquinolone antibiotic. [13] They were often given the fluoroquinolone in conjunction with a corticosteroid or NSAID. Both of these classes of medications are associated with an increased incidence of adverse drug reaction from fluoroquinolones. [10,13] As of yet no scientifically proven effective treatment is known, however patients will definitely benefit from your caring support and appropriate informed care. Of course, other diseases with similar symptoms need to be carefully ruled out. There exists a large community of these patients who share information on the World Wide Web. Their numbers grow as the prescription of fluoroquinolones increases. Many of these patients are professionals like myself who have been affected by these drugs. Thank you for your time and consideration. Todd R. Plumb MD ✏️✏️✏️✏️✏️✏️✏️✏️✏️✏️✏️ References: See this letter along with it's full references in the download section of this page: fq100.org/find-help *💊Medications in the fluoroquinolone class (incl: Cipro/ciprofloxacin, Levaquin (off market)/levofloxacin, Avelox/moxifloxacin etc) in all forms for humans and pets: fq100.org/drug-list ** See more about the medical diagnostic code for fluoroquinolones: fq100.org/find-help ✏️✏️✏️✏️✏️✏️✏️✏️✏️✏️✏️✏️ Find support and resources on our sites: 🌐 Website resources: fq100.org ▶️ YouTube: youtube.com/@FqAntibioticDam… 🐦 X/Twitter: twitter.com/FQ_100 #FQAwareness #Fluoroquinolones #MitochondrialHealth #AntibioticSideEffects #Floxed #Cipro #Levaquin #FQAD

Part II Low-Concentration Macrophage Effects and Why Even Local Fluoroquinolone Exposure May Matter One of the more striking findings in the macrophage literature is that quinolone-induced inflammatory signaling was reported at an extremely low external culture-medium concentration of 0.1 μg/L in RAW264.7 macrophages [1]. That detail matters. The study was not measuring serum concentrations, and it was not measuring directly quantified intracellular concentrations inside macrophages. It was asking a more basic mechanistic question: how little quinolone exposure in the surrounding medium is needed before macrophage inflammatory behavior begins to shift At that level, the authors reported increased pro-inflammatory cytokine signaling, including TNF-α, IL-1β, IL-6, and IL-12, together with activation of pathways such as PI3K/Akt, Notch1, JNK, and JAK2/STAT3, consistent with a more M1-like inflammatory phenotype. Put differently, this work suggests that macrophage inflammatory signaling may respond at a very low exposure threshold. The comparison to human dosing must be made carefully, because 0.1 μg/L in cell culture medium is not the same thing as serum concentration in a patient, nor is it the same as a directly measured intracellular concentration inside a macrophage. Even so, the scale is notable. That concentration equals 0.0001 μg/mL, which is far below levels reached in humans even after low standard oral fluoroquinolone dosing. After a single 250 mg oral dose of ciprofloxacin, mean peak serum concentrations are about 1.2 μg/mL, and mean concentrations at 12 hours are still about 0.1 μg/mL. The same labeling reports that urine concentrations after a single 250 mg dose usually exceed 200 μg/mL during the first two hours and remain around 30 μg/mL at 8–12 hours. Although those are serum and urine values rather than macrophage intracellular concentrations, they show that routine human exposures can be vastly higher than the very low external concentration that was sufficient to alter macrophage signaling in vitro [1–3]. This is also why local exposure from fluoroquinolone eye drops cannot be dismissed automatically. Ophthalmic administration produces a very different pharmacokinetic profile from oral dosing, but it demonstrates the same basic principle: a drug can create very high local tissue-surface exposure even when systemic absorption is much lower. For levofloxacin ophthalmic solution 0.5%, mean tear concentrations after a single drop ranged from 34.9 to 221.1 μg/mL during the first 60 minutes and were still about 17.0 μg/mL at 4 hours and 6.6 μg/mL at 6 hours. In the same product information, plasma concentrations after ophthalmic dosing were low but measurable, ranging from about 0.86 to 2.05 ng/mL one hour after dosing, with a highest maximum mean concentration of about 2.25–2.5 ng/mL during intensive dosing. More concentrated ophthalmic levofloxacin formulations have shown even higher tear concentrations, including values around 757 μg/mL at 15 minutes, together with low-ng/mL plasma exposure [4,5]. The practical implication is not that eye drops should be assumed to produce the same risk profile as tablets or intravenous therapy. That would overstate the evidence. The more careful conclusion is that very low concentrations have already been shown to alter macrophage inflammatory behavior in vitro, while local ophthalmic exposure can generate concentrations at the ocular surface that are orders of magnitude higher than that in vitro threshold, even though blood levels remain much lower than after oral dosing. If macrophages or related immune-responsive cells are involved in tissue-level responses to fluoroquinolones, then local routes of exposure may still be biologically relevant, at least in principle [1,4,5]. This point becomes even more important when viewed together with the broader macrophage and mitochondrial literature. Fluoroquinolones have been reported to drive mitochondrial hyperpolarization and modulate iNOS expression in monocyte-derived macrophage populations [6]. Other work has shown ciprofloxacin-driven increases in IL-1β and TNF-α together with pro-inflammatory macrophage polarization in mammalian models [7]. More broadly, macrophages are now recognized as central regulators of inflammation resolution, tissue repair, fibrosis, and regeneration, while mitochondrial dysfunction in macrophages has been linked to impaired repair and persistent inflammatory signaling [8–12]. Taken together, these studies do not prove that every low or local exposure causes clinically meaningful toxicity in humans. They do, however, support a biologically plausible concern: that even relatively small exposures may be capable of influencing macrophage inflammatory programming under certain conditions, and that high local surface concentrations — such as those achieved with ophthalmic dosing — deserve more attention than they have usually received. If these findings translate, even partially, to humans, the theoretical consequences could be important. Macrophages help determine whether tissues move from acute defense into true recovery. If fluoroquinolones shift macrophages toward a more persistent M1-like, cytokine-driven state, or disturb their mitochondrial function enough to impair their repair role, then one possible downstream effect would be poor resolution of inflammation. In practical terms, that could theoretically contribute to more: persistent tissue irritation, delayed recovery after injury or infection, prolonged inflammatory flares, slower wound healing, and greater difficulty returning to baseline after physical, infectious, or chemical stress. In tissues where macrophages play especially strong regulatory roles, such as the lungs, ocular surface, connective tissue, and mucosal barriers, an abnormal inflammatory or immunometabolic response could in principle amplify local injury or prolong symptoms beyond what would be expected from a short-lived drug exposure alone. This remains a mechanistic projection, not a proven one-to-one clinical outcome [6–12]. The most responsible conclusion, therefore, is neither dismissal nor overstatement. These macrophage studies do not prove that low-dose, local, or ophthalmic fluoroquinolone exposure necessarily causes lasting human disease. What they do show is that macrophage biology can respond to quinolone exposure at very low levels in vitro, and that local tissue exposure from common formulations can greatly exceed those levels. That combination is sufficient to justify a more serious mechanistic discussion and, more importantly, direct human research. Future studies should examine whether comparable macrophage signaling changes occur in human primary macrophages, in patient-derived immune cells, and in clinically relevant exposure models, including low-dose and local routes of administration. Without that work, the human significance of these findings will remain uncertain. With it, the field may better understand whether macrophage dysregulation is one of the missing links between fluoroquinolone exposure and prolonged multi-system symptoms reported by patients [1,4,6]. ✏️Author note: This article was authored by Jerzy Tyszkowski, with AI used only for drafting and language refinement. 🌀 🌀 Disclaimer: This article is an educational, science-based interpretive summary intended for hypothesis generation. It does not establish clinical causation in any individual patient and should not be taken as medical advice, diagnosis, or treatment guidance. The mechanistic implications discussed here are based on experimental and preclinical findings and should be understood as biologically plausible interpretations that still require confirmation in human studies. 💊Medications in the fluoroquinolone class (incl: Cipro/ciprofloxacin, Levaquin (off market)/levofloxacin, Avelox/moxifloxacin etc) in all forms for humans and pets: fq100.org/drug-list Find support and resources on our sites: 🌐 Website & Resources: fq100.org/ ▶️ YouTube: youtube.com/@FqAntibioticDam… 🔵 Facebook: facebook.com/fqtoxicitystudy… 🐦 X/Twitter: twitter.com/FQ_100 References [1] Lang L, Zhang Y, Yang A, Dong J, Li W, Zhang G. Macrophage polarization induced by quinolone antibiotics at environmental residue level. International Immunopharmacology. 2022;106:108596. doi:10.1016/j.intimp.2022.108596. [2] Ciprofloxacin Tablets USP prescribing information. Pharmacokinetics after oral dosing: peak serum concentration after a 250 mg oral dose approximately 1.2 μg/mL; mean 12-hour concentration approximately 0.1 μg/mL. [3] CIPRO prescribing information. After a 250 mg oral dose, urine concentrations usually exceed 200 μg/mL during the first 2 hours and are approximately 30 μg/mL at 8 to 12 hours after dosing. [4] QUIXIN™ (levofloxacin ophthalmic solution 0.5%) prescribing information. Mean tear concentrations 34.9–221.1 μg/mL during the first 60 minutes after a single drop; approximately 17.0 μg/mL at 4 hours and 6.6 μg/mL at 6 hours; plasma concentrations about 0.86–2.05 ng/mL, with highest maximum mean approximately 2.25–2.5 ng/mL during intensive dosing. [5] IQUIX® (levofloxacin ophthalmic solution 1.5%) prescribing information. Mean tear concentration approximately 757 μg/mL at 15 minutes after instillation; plasma concentrations in the low ng/mL range. [6] Hardgrave AW, Dooley M, Maminimini I, Faniyi A, Christodoulidou A, Alshammari Y, March HJ, D’Elia RV, Worthington JJ. Fluoroquinolones directly drive mitochondrial hyperpolarization and modulate iNOS expression in monocyte-derived macrophage populations. Discovery Immunology. 2025;4(1):kyaf018. doi:10.1093/discim/kyaf018. [7] Fan M, Chen S, Weng Y, Li X, Jiang Y, Wang X, Bie M, An L, Zhang M, Chen B, Huang G, Wu J, Zhu M, Shi Q. Ciprofloxacin promotes polarization of CD86 CD206− macrophages to suppress liver cancer. Oncology Reports. 2020;44(1):91–102. doi:10.3892/or.2020.7602. [8] Wang L, Yang K, Xie X, Wang S, Gan H, Wang X, Wei H. Macrophages as Multifaceted Orchestrators of Tissue Repair: Bridging Inflammation, Regeneration, and Therapeutic Innovation. Journal of Inflammation Research. 2025;18:8945–8959. doi:10.2147/JIR.S527764. [9] Cai S, Zhao M, Zhou B, Yoshii A, Bugg D, Villet O, Sahu A, Olson GS, Davis J, Tian R. Mitochondrial dysfunction in macrophages promotes inflammation and suppresses repair after myocardial infarction. Journal of Clinical Investigation. 2023;133(4):e159498. doi:10.1172/JCI159498. [10] Zheng H, Cheng X, Jin L, Shan S, Yang J, Zhou J. Recent advances in strategies to target the behavior of macrophages in wound healing. Biomedicine & Pharmacotherapy. 2023;165:115199. doi:10.1016/j.biopha.2023.115199. [11] Jiang Y, Cai R, Huang Y, et al. Macrophages in organ fibrosis: from pathogenesis to therapeutic targets. Cell Death Discovery. 2024;10(1):487. doi:10.1038/s41420-024-02247-1. [12] Zhao C, Yang Z, Li Y, Wen Z. Macrophages in tissue repair and regeneration: insights from zebrafish. Cell Regeneration. 2024;13(1):12. doi:10.1186/s13619-024-00195-w. #FQAwareness #Fluoroquinolones #MitochondrialHealth #AntibioticSideEffects #Floxed #Cipro #Levaquin #FQAD